CANY
ALDX icon

Caxton Associates (New York)’s Aldeyra Therapeutics ALDX Stock Holding History

Caxton Associates (New York)’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-24,787
Closed -$246K – 482
2023
Q1 		$246K Buy
+24,787
New +$175K 0.04% 382
2022
Q3 		– Sell
-57,860
Closed -$231K – 472
2022
Q2 		$231K Buy
+57,860
New +$199K 0.02% 441

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Caxton Associates (New York)'s ALDX Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Aldeyra Therapeutics (ALDX) in Q2 2023, closing a stake of 24,787 shares — an estimated $246K sold.

Caxton Associates (New York) first reported a position in ALDX in Q2 2022 and held it in 2 quarters. The position peaked at $246K in Q1 2023. 119 funds tracked by Wall St. Rank hold ALDX as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Aldeyra Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 24,787 Aldeyra Therapeutics shares in Q2 2023, an estimated $246K.
  • Caxton Associates (New York) first reported a position in Aldeyra Therapeutics in Q2 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s Aldeyra Therapeutics position peaked at $246K in Q1 2023.
  • 119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.